Can larotrectinib treat late-stage cancer?

Larotrectinib is mainly used to treat malignant tumors carryingNTRK gene fusion. This gene mutation may be present in various cancer types. For patients with tumors carrying NTRK gene fusions, whether early or late, larotrectinib has shown significant therapeutic effects. Clinical trial results show that larotrectinib has achieved good efficacy in some advanced and refractory tumors, leading to durable therapeutic responses. Therefore, larotrectinib is considered a promising treatment option in the treatment of cancer patients carrying NTRK gene fusions, not only for early-stage patients but also in the treatment of advanced tumors. However, the specific treatment plan needs to be determined based on the patient's condition and the doctor's evaluation. Patients should closely follow the doctor's recommendations and regular follow-up during use to ensure the effectiveness and safety of the treatment.